close

Agreements

1 2 3 4 204
Number of results: 4064

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-03-30 BMS (USA - NY) Foundation Medicine (USA - MA) predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) collaboration Cancer - Oncology Establishment of a new subsidiary in the EU
2017-03-30 Merck KGaA (Germany) Avilion (UK) anti IL-17 A/F Nanobody® development Inflammatory diseases Development agreement
2017-03-30 Jazz Pharmaceuticals (Ireland) Nippon Shinyaku (Japan) Defitelio® (defibrotide sodium), Vyxeos® (cytarabine and daunorubicin liposome injection) acute myeloid leukemia, adult and pediatric patients with hepatic veno-occlusive disease (VOD), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) development - commercialisation Cancer - Oncology - Rare diseases Licensing agreement
2017-03-28 Plasticell (UK) Agency for Science, Technology and Research (A*STAR) (Singapore) Nanyang Technological University (Singapore) human stem cell lines research - R&D - licensing R&D agreement
2017-03-28

osteogenic cell therapy and 3D cell culture models

research - R&D Technology - Services R&D agreement
2017-03-28 BMS (USA - NY) The Parker Institute for Cancer Immunotherapy (USA - CA) the Cancer Research Institute (CRI) (USA - NY) clinical research Cancer - Oncology Clinical research agreement
2017-03-28 Selvita (Poland) Menarini (Italy) SEL24 licensing Cancer - Oncology Licensing agreement
2017-03-28 RegenXBio (USA - MD) nomination Rare diseases - Genetic diseases Nomination
2017-03-27 Xbrane Biopharma (Sweden) Spherotide production facility in Italy validation of a production plant Technology -Services Validation of a production plant
2017-03-27 Alexion Pharmaceuticals (USA - CT) nomination Rare diseases - Genetic diseases Nomination
2017-03-24 PureTech Health (USA - MA) Novartis (Switzerland) two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway diseases related to immunosenescence licensing Immunological diseases Establishment of a new subsidiary in the EU
2017-03-24 C4 Therapeutics (USA - MA) Calico (USA - CA) small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins diseases of aging, including cancer development commercialisation Cancer - Oncology Development agreement
2017-03-23 ImmunoCellular Therapeutics (USA - CA) Memgen (USA - TX ICT-107, ICT-140 and ISF35 clinical research Cancer - Oncology Clinical research agreement
2017-03-23 Retrophin (USA - CA) nomination Rare diseases Nomination
2017-03-23 Novosanis (Belgium) MDxHealth (Belgium) UrNCollect™ distribution Technology - Services - Diagnostic Distribution agreement
2017-03-22 GSK (UK) Regeneron Pharmaceuticals (USA - NY) UK Biobank (UK) genetic sequence data collaboration Technology - Services Collaboration agreement
2017-03-21 Pierre Fabre (France) H-Immune (France) fully human monoclonal antibody candidates research development Cancer - Oncology R&D agreement
2017-03-21 X-Chem (USA - MA) Ono Pharmaceutical (Japan) small molecules development commercialisation Cancer - Oncology Development agreement
2017-03-21 Partners test now Compound: Disease: Type of agreement: Therapeutic_area:asdsadas Plant acquisition
2017-03-21 MDxHealth (Belgium) Lab21 (UK), part of the Novacyt Group (France) SelectMDx™ for Prostate Cancer test prostate cancer distribution Cancer - Oncology - Diagnostic Distribution agreement